



## INSPIR THERAPEUTICS, INC. (OTCQB: NSPX)

Inspyr Therapeutics, Inc. is a Los Angeles-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. Inspyr's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

## MANAGEMENT TEAM

### Chris Lowe

President, CEO and Director

### Michael Elliott

Vice President of Clinical Operations

### Matthew Boxer, Ph.D.

Vice President and Co-head of Translational Medicine

### David Maloney, Ph.D.

Vice President and Co-head of Translational Medicine

## RECENT NEWS

### Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health

Oct 23 2017, 9:00 AM EDT

### Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital

Oct 4 2017, 9:00 AM EDT

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

## INSPIR THERAPEUTICS, INC.

31200 Via Colinas  
Suite 200  
Westlake Village, CA 91362  
USA

## STOCK OVERVIEW

Symbol	NSPX
Exchange	OTCQB
Shares OS	9,578,929
Market Cap	\$239473
Last Price	\$0.025
52-Week Range	\$0.015 - \$0.55
Fiscal Year End	December 31

## INVESTOR RELATIONS

T: 818-661-6302  
lcali@inspyrtx.com